Albania
Bośnia i Hercegowina
Bułgaria
Chorwacja
Cypr
Czarnogóra
Czechy
Dania
Estonia
Hiszpania
Kosowo
Litwa
Łotwa
Luksemburg
Macedonia
Niemcy
Polska
Portugalia
Rumunia
Serbia
Słowacja
Słowenia
Szwajcaria
Szwecja
Turcja
Węgry
Wielka Brytania
Włochy
UAE
Hong Kong
Kuwejt
Liban
RPA
Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 801 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 77 |
| 802 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 23 |
| 803 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 804 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | United Kingdom | 53 |
| 805 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 75 |
| 806 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 807 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 8 |
| 808 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 63 |
| 809 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 38 |
| 810 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 811 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 69 |
| 812 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 31 |
| 813 | Bone Marrow Family | Allogeneic | Acute Myleogenous Leukemia, alloPBST 7/2025 | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 814 | Bone Marrow | Allogeneic | Aplastic Anemia | Hematology | 2025 | Standard Therapy | Spain | 15 |
| 815 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Norway | 55 |
| 816 | Bone Marrow | Allogeneic | Inherited Immune System Disorder | Hematology | 2025 | Standard Therapy | France | 3 |
| 817 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 7 |
| 818 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Ukraine | 36 |
| 819 | Bone Marrow | Allogeneic | Inherited Immune System Disorder | Hematology | 2025 | Standard Therapy | France | 10 |
| 820 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 76 |
| 821 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 39 |
| 822 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | South Africa | 6 |
| 823 | Bone Marrow | Allogeneic | Wiskott-Aldrich syndrome | Hematology | 2025 | Standard Therapy | Turkey | 6 |
| 824 | Bone Marrow | Allogeneic | Combined immnunodeficiency | Hematology | 2025 | Standard Therapy | Ukraine | 3 |
| 825 | Bone Marrow | Allogeneic | Chronic Granulomatous Disease | Hematology | 2025 | Standard Therapy | Poland | 3 |
| 826 | Bone Marrow | Allogeneic | Mixed Phenotype Acute Leukemia | Hematology | 2025 | Standard Therapy | Poland | 13 |
| 827 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 7 |
| 828 | Bone Marrow | Allogeneic | B-cell precursor Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 56 |
| 829 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 43 |
| 830 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 19 |
| 831 | Bone Marrow | Allogeneic | Very Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 12 |
| 832 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 5 |
| 833 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 10 |
| 834 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 6 |
| 835 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 44 |
| 836 | Bone Marrow | Allogeneic | Paroxysmal Nocturnal Hemoglobinuria | Hematology | 2025 | Standard Therapy | Poland | 25 |
| 837 | Bone Marrow | Allogeneic | Juvenile Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 4 |
| 838 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | USA | 21 |
| 839 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Italy | 12 |
| 840 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Hungary | 10 |
| 841 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Czechia | 68 |
| 842 | Bone Marrow | Allogeneic | Adrenoleukodystrophy | Hematology | 2025 | Standard Therapy | Poland | 53 |
| 843 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 4 |
| 844 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | France | 4 |
| 845 | Bone Marrow | Allogeneic | Paroxysmal Nocturnal Hemoglobinuria | Hematology | 2025 | Standard Therapy | Norway | 18 |
| 846 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Spain | 24 |
| 847 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Belarus | 5 |
| 848 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 849 | Bone Marrow | Allogeneic | diamond-Balckfan anemia | Hematology | 2025 | Standard Therapy | Germany | 11 |
| 850 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 57 |
| 851 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 61 |
| 852 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | France | 3 |
| 853 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Belarus | 1 |
| 854 | Bone Marrow | Allogeneic | pB-Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 15 |
| 855 | Bone Marrow | Allogeneic | OHID XIAP – Other Histiocytic Disorders / X-Linked Inhibitor of Apoptosis Protein | Hematology | 2025 | Standard Therapy | Switzerland | 2 |
| 856 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 46 |
| 857 | Bone Marrow | Allogeneic | Acquired Idiopathic Sideroblastic Anemia | Hematology | 2025 | Standard Therapy | Russian Federation | 5 |
| 858 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 10 |
| 859 | Bone Marrow | Allogeneic | Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | USA | 47 |
| 860 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | CROATIA | 11 |
| 861 | Bone Marrow | Allogeneic | Juvenile myelomonocytic leukemia | Hematology | 2025 | Standard Therapy | Poland | 5 |
| 862 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Brazil | 12 |
| 863 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Australia | 8 |
| 864 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 3 |
| 865 | Bone Marrow | Allogeneic | Myelodysplatic Syndrome | Hematology | 2025 | Standard Therapy | USA | 60 |
| 866 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Russia | 36 |
| 867 | Bone Marrow | Allogeneic | Thalassemia major | Hematology | 2025 | Standard Therapy | Turkey | 10 |
| 868 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 58 |
| 869 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 2 |
| 870 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | USA | 18 |
| 871 | Bone Marrow | Allogeneic | Other Non-Malignant Disease, Specify | Hematology | 2025 | Standard Therapy | USA | 17 |
| 872 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 15 |
| 873 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 15 |
| 874 | Bone Marrow | Allogeneic | aplastic anemia | Hematology | 2025 | Standard Therapy | Belgium | 36 |
| 875 | Bone Marrow | Allogeneic | Primary Refractory | Hematology | 2025 | Standard Therapy | Ireland | 27 |
| 876 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 39 |
| 877 | Bone Marrow | Allogeneic | Sickle Cell Disease (SCD) | Hematology | 2025 | Standard Therapy | Italy | 8 |
| 878 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 68 |
| 879 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 58 |
| 880 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 1 |
| 881 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2025 | Standard Therapy | United Kingdom | 13 |
| 882 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Denmark | 38 |
| 883 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 17 |
| 884 | Bone Marrow | Allogeneic | Fanconi Anemia | Hematology | 2025 | Standard Therapy | Poland | 11 |
| 885 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 9 |
| 886 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 3 |
| 887 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | France | 9 |
| 888 | Bone Marrow | Allogeneic | Fanconi Anemia | Hematology | 2025 | Standard Therapy | Poland | 8 |
| 889 | Bone Marrow | Allogeneic | Immune Deficiency | Hematology | 2025 | Standard Therapy | United Kingdom | 10 |
| 890 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Germany | 12 |
| 891 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | USA | 20 |
| 892 | Bone Marrow | Allogeneic | Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Turkey | 17 |
| 893 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 13 |
| 894 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Canada | 22 |
| 895 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 15 |
| 896 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Italy | 8 |
| 897 | Bone Marrow | Allogeneic | Inherited Immune System Disorder | Hematology | 2025 | Standard Therapy | France | 3 |
| 898 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Italy | 2 |
| 899 | Bone Marrow | Allogeneic | Bone Marrow Failure | Hematology | 2025 | Standard Therapy | Netherlands | 23 |
| 900 | Bone Marrow | Allogeneic | Chronic Granulomatous Disease | Hematology | 2025 | Standard Therapy | Italy | 6 |